Given the length of the journey for our valve from design, development, test, animal studies, human trials, marketing and device approval.
If a 3D printed valve delivers the right haemodynamic function in a human with no calcification, rejection and other issues.
How far from market, based on where they are now based on the article?
A decade, longer??
Other than another contender in the valve space competing for capital investment, I dont see this as much of a threat in the short to medium term.
If current investment in AVR is to be successful, investor returns will have been well and truly achieved by then.
The only question is will it be successful for current investors.
Add to My Watchlist
What is My Watchlist?
